A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/295 (2006.01) A61K 39/05 (2006.01) A61K 39/08 (2006.01) A61K 39/10 (2006.01) A61K 39/13 (2006.01) A61K 39/245 (2006.01) C07K 14/04 (2006.01) C07K 14/045 (2006.01) C07K 14/05 (2006.01) A61K 39/00 (2006.01)
Patent
CA 2185540
The present invention provides a composition where a CTL peptide is presented in such a way as to maximise the attachment of peptide to class 1 MHC molecules on the external surface of cells and the subsequent processing of these cells in the optimal way to induce high-affinity CD8+ CTL responses. Preferably, the composition comprises a water-in-oil formulation including at least one antigen to which the individual will mount an anamnestic response and at least one cytotoxic T-cell epitope.
Composition dans laquelle un peptide de lymphocyte T cytotoxique est présenté de manière à maximiser la fixation du peptide aux molécules du complexe majeur d'histocompatibilité de classe 1 à la surface externe des cellules, et traitement ultérieur optimisé de ces cellules dans le but d'induire des réponses de lymphocytes T cytotoxiques CD¿8??+¿ à affinité élevée. De préférence, la composition comporte une formulation eau-dans-huile comprenant au moins un antigène qui suscitera chez l'individu une réponse anamnestique, ainsi qu'au moins un épitope de lymphocyte T cytotoxique.
Cox John Cooper
Elliott Suzanne Louise
Suhrbier Andreas
Biotech Australia Pty Limited
Biotech Australia Pty. Limited
Commonwealth Scientific And Industrial Research Organisation
Csl Limited
Swabey Ogilvy Renault
LandOfFree
Formulation for use in inducing cytotoxic t-cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulation for use in inducing cytotoxic t-cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation for use in inducing cytotoxic t-cells will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1621943